Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2023-02-01 00:00:00 ET · period of report 2023-01-31 · accession 0001867096-23-000019 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-01 | 2023-01-31 | XERS | JOHNSON KENNETH ERLAND | See Remarks | A - Grant | $0.00 | +100.0K | 269.8K | +59% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-31 | A | A | 100,000 | $0.00 | 269,783 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. (F2) These shares include 1,460 shares that were purchased on June 30, 2022 and 1,700 shares that were purchased on December 31, 2022 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan. |